dabigatran has been researched along with Budd-Chiari Syndrome in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Aigner, E; Balcar, L; Bartl, S; Datz, C; Gensluckner, S; Hametner-Schreil, S; Hofer, H; Lampichler, K; Lindorfer, A; Mandorfer, M; Pomej, K; Reiberger, T; Schäfer, B; Scheiner, B; Schöfl, R; Semmler, G; Trauner, M; Zoller, H | 1 |
Gamanagatti, SR; Kumar, R; Rout, G; Sharma, S | 1 |
Husová, L | 1 |
3 other study(ies) available for dabigatran and Budd-Chiari Syndrome
Article | Year |
---|---|
Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Austria; Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Dabigatran; End Stage Liver Disease; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Retrospective Studies; Severity of Illness Index; Vitamin K | 2023 |
Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.
Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Dabigatran; Endovascular Procedures; Female; Follow-Up Studies; Humans; Male; Retrospective Studies; Stents; Vitamin K; Young Adult | 2020 |
Use of idarucizumab in clinical practice: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Budd-Chiari Syndrome; Dabigatran; Hemorrhage; Humans; Liver Transplantation | 2019 |